Predictive value of KRAS mutations in chemoresistant CRC

被引：30
|
作者：
Lievre, Astrid [2 ]
Laurent-Puig, Pierre [1 ]
机构：
[1] Univ Paris 05, Sch Med, F-75006 Paris, France
[2] INSERM Lab, Paris, France
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 06期
关键词：
METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; CETUXIMAB; PANITUMUMAB;
D O I：
10.1038/nrclinonc.2009.69
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
引用
收藏
页码：306 / 307
页数：3
相关论文
共 50 条
  • [1] Predictive value of KRAS mutations in chemoresistant CRC
    Astrid Lièvre
    Pierre Laurent-Puig
    Nature Reviews Clinical Oncology, 2009, 6 : 306 - 307
  • [2] Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
    Lavacchi, Daniele
    Fancelli, Sara
    Roviello, Giandomenico
    Castiglione, Francesca
    Caliman, Enrico
    Rossi, Gemma
    Venturini, Jacopo
    Pellegrini, Elisa
    Brugia, Marco
    Vannini, Agnese
    Bartoli, Caterina
    Cianchi, Fabio
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Prognostic and predictive value of circulating KRAS mutations in stage IV pancreatic cancer
    Hussung, S.
    Follo, M.
    Michalczyk, S.
    Hajkova, A.
    Fritsch, K.
    Boerries, M.
    von Bubnoff, N.
    Scherer, F.
    Duyster, J.
    Fritsch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 124 - 125
  • [4] Prognostic and predictive value of PIK3CA mutations in metastatic CRC (mCRC)
    Tan, Elaine
    Fan, Wenyi
    Schell, Michael
    Sahin, Ibrahim
    Fleming, Jason
    Knepper, Todd
    Xie, Hao
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Mutations in KRAS render cetuximab therapy for advanced CRC ineffective
    Nature Clinical Practice Gastroenterology & Hepatology, 2009, 6 (2): : 64 - 64
  • [6] Genetic, immunologic and prognostic heterogeneity in CRC patients with KRAS mutations
    Li, Ruiqian
    Zhang, Hushan
    Wang, Qilin
    Yang, Hong
    Bai, Yu
    Hu, Chen
    Wu, Hongyi
    Zhang, Chongjian
    Wang, Ziyong
    Wang, Qiwei
    Xu, Pengjie
    Li, Jun
    CANCER RESEARCH, 2022, 82 (12)
  • [7] PROGNOSTIC AND PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN PATIENTS ENROLLED IN THE MRC FOCUS TRIAL
    Richman, S. D.
    Chambers, P.
    Elliott, F.
    Daly, C.
    Barrett, J.
    Taylor, G.
    Quirke, P.
    Seymour, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 166 - 166
  • [8] Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer
    Sun, Jong-Mu
    Hwang, Deok Won
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    PLOS ONE, 2013, 8 (05):
  • [9] PROGNOSTIC AND PREDICTIVE VALUE OF KRAS MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER
    Hwang, Deok Won
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1075 - S1075
  • [10] Prognostic and Predictive Value of KRAS Mutation in NSCLC
    Yamamoto, Satomi
    Washington, Laurie
    Komiya, Takefumi
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : E128 - +
12345